Skip to main content
Clinical Trials/NCT02759926
NCT02759926
Unknown
Not Applicable

The Role of Bitter Taste Receptors Expressed in the Gastrointestinal Tract in Altering Food Intake and Gastrointestinal Motility

Universitaire Ziekenhuizen KU Leuven0 sites98 target enrollmentAugust 2011

Overview

Phase
Not Applicable
Intervention
Denatonium benzoate
Conditions
Healthy
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
98
Primary Endpoint
Change in gastrointestinal motility measured by antroduodenal high-resolution manometry
Last Updated
10 years ago

Overview

Brief Summary

In this study, the investigators aimed at evaluating the role of bitter taste receptors in the gastrointestinal tract (GIT). Intragastric or intraduodenal administration of denatonium benzoate (DB) or quinine hydrochloride were compared with placebo administration for their effects on lingual sensitivity, gastrointestinal motility (both in the fasted and fed state), gut hormone release (motilin, ghrelin, glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK)) and food intake. Differences between lean and obese subjects will be evaluated.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
November 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • BMI\>30 kg/m² for the obese volunteers
  • BMI\<30 kg/m² for the lean volunteers
  • Subject is capable and willing to give informed consent
  • Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception

Exclusion Criteria

  • Female volunteer is pregnant or breastfeeding
  • Gastrointestinal diseases, major abdominal surgery
  • Major psychiatric illnesses
  • Volunteers that use drugs affecting the GIT or the central nervous system (CNS)
  • Volunteers that suffer from diabetes mellitus
  • Volunteers suffering from an endocrine disease such as diabetes, Cushing's disease, Addison's disease, hypothalamic tumor...
  • Volunteers that have undergone surgical procedure for weight loss

Arms & Interventions

Denatonium benzoate intragastric

1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.

Intervention: Denatonium benzoate

Quinine hydrochloride intragastric

10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.

Intervention: Quinine hydrochloride

Tap water intragastric

An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.

Intervention: Tap water

Denatonium benzoate intraduodenal

1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.

Intervention: Denatonium benzoate

Quinine hydrochloride intraduodenal

10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.

Intervention: Quinine hydrochloride

Tap water intraduodenal

An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.

Intervention: Tap water

Outcomes

Primary Outcomes

Change in gastrointestinal motility measured by antroduodenal high-resolution manometry

Time Frame: 2 hours after administration, continuous measurement with high resolution manometry

Secondary Outcomes

  • Change in gut hormone release measured by specific radioactive immunoassays(2 hours after administration, blood sample every 10 min)
  • Change in food intake measured by the caloric content of the meal(ad libitum food intake for 1 hour, 40 min after administration)
  • Change in subjective hunger and satiety scores measured by visual analogue scales of 100 mm(2 hours after administration, assessment every 5 min)

Similar Trials